EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia

Zhao Yin, Zurong Yao, Dandan Chen, Yu Zhang, Guangyang Weng, Xin Du, Dongjun Lin, Jie Xiao, Zhiqiang Sun, Hongyu Zhang, Xinquan Liang, Ziwen Guo und 7 weitere

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05861-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Zhao Yin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 5105…. Hauptthemen laut MEDLINE: Homoharringtonine, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Azacitidine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

T(8;21)(q22;q22.1)/AML1-ETO positive acute myeloid leukemia (AE-AML) is sensitive to conventional chemotherapy with a favorable prognosis. However, recent small case reports suggest the limited effectiveness of venetoclax (VEN) and hypomethylating agents (HMA) in treating AE-AML. The aim of this retrospective study was to evaluate the effectiveness of VEN plus AZA (VA) in AE-AML and explore whether adding homoharringtonine (HHT) to VA (VAH) could improve the response.

Methods

Patients who received VEN plus AZA and HHT (VAH) or VEN plus AZA (VA) regimens were included in this retrospective study. The endpoints of this study were to evaluate the rate of composite complete remission (CRc), measurable residual disease (MRD), event-free survival (EFS), overall survival (OS), and relapse between VAH and VA groups.

Results

A total of 32 AE-AML patients who underwent VA or VAH treatments (newly diagnosed with VA, ND-VA, n = 8; relapsed/refractory with VA, R/R-VA, n = 10; relapsed/refractory with VAH, R/R-VAH, n = 14) were included. The CR (complete remission) /CRi (CR with incomplete count recovery) rate of ND-VA, R/R-VA and R/R-VAH were 25%, 10%, and 64.3%, respectively. Measurable residual disease (MRD) negative was observed in 66.7% of R/R-VAH and none of VA-R/R patients. Co-occurring methylation mutations are associated with poor outcomes with VA but exhibit a more favorable response with VAH treatment. Additionally, patients with c-kit mutation presented inferior outcomes with both VEN-based regimens. All regimens were tolerated well by all patients.

Conclusion

Our data confirmed the poor response of VA in AE-AML, whether used as frontline or salvage therapy. Adding HHT to VA may improve outcomes and enhance the efficacy of VEN in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HomoharringtonineLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicAzacitidineSulfonamidesCore Binding Factor Alpha 2 SubunitRUNX1 Translocation Partner 1 ProteinAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedFemaleRetrospective StudiesAgedAdultOncogene Proteins, FusionYoung Adult

Stichwörter der Autor:innen

AML1/ETO positiveAcute myeloid leukemiaAzacitidineHomoharringtonineVenetoclax

Substanzen

HomoharringtoninevenetoclaxBridged Bicyclo Compounds, HeterocyclicAzacitidineSulfonamidesCore Binding Factor Alpha 2 SubunitRUNX1 Translocation Partner 1 ProteinAML1-ETO fusion protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China.
  • Department of Hematology, Shenzhen Second People's Hospital, Shenzhen, 518035, P.R. China.
  • Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518107, P.R. China.
  • Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, P.R. China.
  • Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, 510086, P.R. China.
  • Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, 518036, P.R. China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Yin, Z., Yao, Z., Chen, D., Zhang, Y., Weng, G., Du, X., Lin, D., Xiao, J., Sun, Z., Zhang, H., Liang, X., Guo, Z., Zhao, W., Xuan, L., Jiang, X., Shi, P., Liu, Q., Ping, B., & Yu, G. (2024). Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05861-9

Vancouver

Yin Z, Yao Z, Chen D, Zhang Y, Weng G, Du X, et al. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05861-9

BibTeX
@article{Yin2024,
  author = {Yin, Zhao and Yao, Zurong and Chen, Dandan and Zhang, Yu and Weng, Guangyang and Du, Xin and Lin, Dongjun and Xiao, Jie and Sun, Zhiqiang and Zhang, Hongyu and Liang, Xinquan and Guo, Ziwen and Zhao, Weihua and Xuan, Li and Jiang, Xuejie and Shi, Pengcheng and Liu, Qifa and Ping, Baohong and Yu, Guopan},
  title = {Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05861-9}
}
Kostenlos starten →